Skip to content

Clinical efficacy and mechanism study of tDCS-enhanced MI-BCI in improving upper limb dysfunction after stroke

Clinical efficacy and mechanism study of tDCS-enhanced MI-BCI in improving upper limb dysfunction after stroke

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600121051
Enrollment
Unknown
Registered
2026-03-24
Start date
2026-04-01
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

Group A:Task-state tDCS+MI-BCI
Group B:Resting-state tDCS+MI-BCI
Group C:Task-state pseudo tDCS + MI-BCI

Sponsors

Shanghai Yangzhi rehabilitation hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Diagnosed as stroke (including ischemic stroke or hemorrhagic stroke) by cranial CT or MRI examination; 2.Age: 18 ~75 years; Duration of illness: 2 weeks~6 months; 3.Accuracy rate of the BCI task=2 levels; 5.MMSE score >= 24 points.

Exclusion criteria

Exclusion criteria: 1.Secondary paralysis: Movement disorders of the upper limbs caused by trauma, neurodegenerative diseases (such as Parkinson's disease, amyotrophic lateral sclerosis), or congenital neuromuscular disorders (such as spinal muscular atrophy). 2.Comorbid severe systemic diseases: Comorbid with severe cardiovascular and cerebrovascular diseases (such as uncontrolled hypertension, coronary heart disease, epilepsy), mental disorders (such as depression, schizophrenia); 3.Cranial bone defects or after cardiac pacemaker or DBS implantation surgeries, these factors can affect the safety of tDCS stimulation. 4.Skin or body surface contraindications: If the skin on the affected upper limb is damaged or inflamed, it will interfere with the attachment of the electrode. 5.Drug interference: Currently taking antiepileptic drugs (such as benzodiazepines), sedatives (such as benzodiazepines, barbiturates); 6.Currently undergoing or plans to undergo other neuroregulation techniques within the next 4 weeks.

Design outcomes

Primary

MeasureTime frame
Fugl-Meyer As- sessment-Upper Extremities;

Secondary

MeasureTime frame
Modified Barthel Index;Wolf motor function ;Task completion rate;

Countries

China

Contacts

Public ContactDan Huang

Shanghai Yangzhi rehabilitation hospital

helena14@foxmail.com+86 21 3773 0011

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 4, 2026